北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科  > 期刊论文
学科主题: 临床医学
题名:
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
作者: Qin, Shukui1; Bi, Feng2; Jin, Jie3; Cheng, Ying4; Guo, Jun5; Ren, Xiubao6; Huang, Yiran7; Tarazi, Jamal8; Tang, Jie9; Chen, Connie9; Kim, Sinil8; Ye, Dingwei10
关键词: axitinib ; renal cell carcinoma ; sorafenib ; vascular endothelial growth factor receptor inhibitor
刊名: ONCOTARGETS AND THERAPY
发表日期: 2015
DOI: 10.2147/OTT.S83302
卷: 8
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biotechnology & Applied Microbiology ; Oncology
研究领域[WOS]: Biotechnology & Applied Microbiology ; Oncology
关键词[WOS]: JAPANESE PATIENTS ; PHASE-II ; OPEN-LABEL ; PROGNOSTIC-FACTORS ; CLINICAL-PRACTICE ; KIDNEY CANCER ; AXIS TRIAL ; EFFICACY ; SAFETY ; SUNITINIB
英文摘要:

Background: This registrational trial evaluated the efficacy, safety, and patient-reported outcomes of axitinib versus sorafenib as a second-line treatment in Asian patients with clear-cell metastatic renal cell carcinoma (mRCC).

Methods: In this open-label, multicenter study, previously treated Asian patients with clear-cell mRCC were stratified by Eastern Cooperative Oncology Group performance status and prior therapy and randomized in a 2:1 ratio to receive axitinib (5 mg twice daily) or sorafenib (400 mg twice daily). The primary end point was progression-free survival (PFS) assessed by a masked independent review committee.

Results: A total of 204 Asian patients received axitinib (n=135) or sorafenib (n=69). Median PFS (95% confidence interval [CI]) was 6.5 (4.7-9.1) months with axitinib versus 4.8 (3.0-6.5) months with sorafenib (hazard ratio, 0.731; 95% CI, 0.506-1.058; one-sided P=0.0531). The objective response rate (95% CI) was 23.7% (16.8%-31.8%) with axitinib versus 10.1% (4.2%-19.8%) with sorafenib. Common, grade >= 3, all-causality adverse events were hypertension (19.3%), weight decrease (5.2%), and proteinuria (5.2%) with axitinib and hypertension (8.7%) and palmar-plantar erythrodysesthesia (7.2%) with sorafenib. In a time-to-deterioration composite end point of death, progression, and worsening of Functional Assessment of Cancer Therapy Kidney Symptom Index score, patients treated with axitinib demonstrated a 17%-24% risk reduction compared with sorafenib-treated patients.

Conclusion: Axitinib is clinically active and well tolerated in previously treated Asian patients with mRCC, consistent with the results from the global Phase III trial. These results establish axitinib as a second-line treatment option for Asian patients with mRCC.

语种: 英语
项目资助者: Pfizer Inc
WOS记录号: WOS:000355868800003
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53841
Appears in Collections:北京大学第一临床医学院_泌尿外科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Dept Urol, Beijing 100871, Peoples R China
2.Tianjin Oncol Hosp, Dept Biol Treatment, Tianjin, Peoples R China
3.Pfizer Oncol, Clin Dev, San Diego, CA USA
4.Pfizer Inc, Global Outcomes Res, New York, NY USA
5.Nanjing Bayi Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
6.Sichuan Univ, West China Hosp, Dept Med Oncol, Chengdu 610064, Sichuan Provinc, Peoples R China
7.Jilin Prov Canc Hosp, Dept Oncol, Changchun, Jilin Province, Peoples R China
8.Peking Univ, Canc Hosp Inst, Dept Renal Canc & Melanoma, Beijing 100871, Peoples R China
9.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Urol, Shanghai 200030, Peoples R China
10.Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai 200032, Peoples R China

Recommended Citation:
Qin, Shukui,Bi, Feng,Jin, Jie,et al. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study[J]. ONCOTARGETS AND THERAPY,2015,8.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Qin, Shukui]'s Articles
[Bi, Feng]'s Articles
[Jin, Jie]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Qin, Shukui]‘s Articles
[Bi, Feng]‘s Articles
[Jin, Jie]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace